The biological activity of MENOPUR® is
determined using the bioassays for FSH (ovarian weight gain assay in female
rats) and LH (seminal vesicle weight gain assay in male rats), modified to
increase the accuracy and reproducibility of these assays. The FSH and LH
activity assays are standardized using the Fourth International Standard for
Urinary FSH and Urinary LH, November 2000, by the Expert Committee on Biological
Standardization of the W orld Health Organization (WHO ECBS). Both FSH and LH
are glycoproteins that are acidic and water soluble. Human Chorionic
Gonadotropin (hCG) is detected in MENOPUR® .

MENOPUR® has been mixed in vitro with Bravelle® with no evidence of aggregation.

What are the possible side effects of menotropins (Menopur, Repronex)?

Stop using menotropins and seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives).

Less than 2% of female patients treated with menotropins develop ovarian hyperstimulation syndrome (OHSS), especially after the first cycle of therapy. Symptoms of OHSS include swelling of the hands or legs, abdominal pain and swelling, shortness of breath, weight gain, and nausea or vomiting. OHSS can be fatal. Notify your doctor immediately or seek emergency medical attention if...

What are the precautions when taking menotropins injection (Menopur)?

Before using this medication, tell your doctor or pharmacist if you are allergic to it; or to other products containing follicle stimulating hormone or luteinizing hormone; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.